NEW YORK, NY, December 18, 2025 /24-7PressRelease/ -- CD BioSciences recently launched a complete one-stop anti-aging drug development service package for pharmaceutical companies, research institutions and academic investigators who are developing cutting-edge anti-aging drugs. As a professional CRO in aging research field, CD BioSciences combines cutting-edge technical platforms with industry-leading experience to support partners throughout the entire anti-aging drug development cycle, from early discovery to preclinical stages.

At the core of CD BioSciences' offerings is its diversified anti-aging drug discovery services, which provide customized solutions for drug discovery across a wide range of targets and drug types. In terms of targets, the service covers key molecules and signaling pathways such as AMPK, mTOR, SIRT1, NF-κB, p53, and PI3K, which are closely associated with aging mechanisms. For drug types, it encompasses mainstream anti-aging drug categories including senolytics, senomorphics, calorie restriction mimetics, autophagy inducers, anti-inflammatory drugs, antioxidants, telomerase activators, and mitochondrial modulators, fully meeting the diversified needs of clients in target verification and lead compound screening.

CD BioSciences' anti-aging drug development services further extend to a complete preclinical development system, covering multiple key links to ensure the scientificity and reliability of drug development data. Its anti-aging pharmacology services include both in vitro and in vivo evaluations to verify the therapeutic efficacy of candidate drugs. The in vitro ADME services and in vivo pharmacokinetic services enable early assessment of the pharmacokinetic behaviors of drugs, providing critical data for dose optimization, while the in vitro toxicity testing, non-GLP toxicology, and safety pharmacology services comprehensively evaluate the potential toxic effects of anti-aging drugs on cardiovascular, respiratory, central nervous and other key physiological systems, laying a solid foundation for subsequent development stages.

As a specialized aging disease model CRO, CD BioSciences has built a comprehensive and customizable preclinical aging model platform as well. The model customization services cover four major categories, including organ-specific aging models (skin, cardiac, liver, lung, kidney, muscle aging models), general aging models (cellular senescence models, yeast aging models, aging mouse/rat models, non-human primate aging models, zebrafish aging models), longevity models (long-lived yeast strains, Drosophila, genetic mouse models, Fukomys mole-rat and naked mole-rat models), and aging-related disease models (neurodegenerative disease models, cardiovascular disease models, bone loss models, respiratory disease models, eye disease models, sarcopenia models, progeria models). These models can effectively assist clients in uncovering aging mechanisms, validating therapeutic targets, and evaluating the efficacy and safety of anti-aging drugs.

CD BioSciences has long been committed to longevity and anti-aging research, and the launch of the one-stop anti-aging drug development services is to address the key challenges of lengthy timelines and high barriers to entry in anti-aging R&D. CD BioSciences will continue to optimize its technical platforms and service systems and strive to become a top-selected partner for worldwide institutions in the field of anti-aging drug development, promoting the innovation and transformation of anti-aging therapeutics.

About CD BioSciences
CD BioSciences is a preclinical research service provider focusing on anti-aging drug development, offering one-stop services spanning drug discovery, pharmacology, pharmacokinetics, and safety evaluation. With a team of experienced scientists and advanced facilities, CD BioSciences is dedicated to supporting global anti-aging drug R&D industry and accelerating the realization of innovative drug pipelines.

# # #